GANX — Gain Therapeutics Share Price
0.000.00%
Last trade - 00:00- $60.62m
- $50.67m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 8.26 | ||
| Price to Tang. Book | 8.41 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -247.79% | ||
| Return on Equity | -204.95% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.03 | 0.16 | 0.14 | 0.06 | n/a | 0.04 | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of glucocerebrosidase or GCase, function in the lysosome, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 26th, 2020
- Public Since
- March 18th, 2021
- No. of Shareholders
- 73
- No. of Employees
- 23
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 29,427,225
- Address
- 4800 Montgomery Lane, Suite 220, BETHESDA, 20814
- Web
- https://www.gaintherapeutics.com/
- Phone
- +1 3015001556
- Auditors
- Ernst & Young AG
Upcoming Events for GANX
Gain Therapeutics Inc Annual Shareholders Meeting
Gain Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Gain Therapeutics Inc Earnings Release
Similar to GANX
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Gain Therapeutics share price?
As of Today at 20:45 UTC, shares in Gain Therapeutics are trading at $2.06. This share price information is delayed by 15 minutes.
How has the Gain Therapeutics share price performed this year?
Shares in Gain Therapeutics last closed at $2.06 and the price had moved by -29.69% over the past 365 days. In terms of relative price strength the Gain Therapeutics share price has underperformed the S&P500 Index by -36.6% over the past year.
What are the analyst and broker recommendations for Gain Therapeutics?
The overall consensus recommendation for Gain Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Gain Therapeutics dividend yield?
Gain Therapeutics does not currently pay a dividend.
Does Gain Therapeutics pay a dividend?
Gain Therapeutics does not currently pay a dividend.
When does Gain Therapeutics next pay dividends?
Gain Therapeutics does not currently pay a dividend.
How do I buy Gain Therapeutics shares?
To buy shares in Gain Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Gain Therapeutics?
As of the previous close price of $2.06, shares in Gain Therapeutics had a market capitalisation of $60.62m.
Where are Gain Therapeutics shares listed?
Here are the trading details for Gain Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: GANX
What kind of share is Gain Therapeutics?
Based on an overall assessment of its quality, value and momentum Gain Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Gain Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Gain Therapeutics is $8.00. That is 288.35% above the last closing price of $2.06.
Analysts covering Gain Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.79 for the next financial year.
Find out moreWhat is the trend in the Gain Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Gain Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -10.8%.
As of the last closing price of $2.06, shares in Gain Therapeutics were trading +11.28% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Gain Therapeutics PE Ratio?
The Gain Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.06.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Gain Therapeutics?
We do not have data on Gain Therapeutics' directors